Active, not recruitingPhase 1NCT05290597

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

Studying Lymphoma

Last synced from ClinicalTrials.gov May 12, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Principal Investigator: Morteza Aghmesheh
Southern Medical Day Care Centre
Intervention: IBI363(biological)
Enrollment: 40 target
Eligibility: 18 years · All sexes
Timeline: 2022 – 2026

Study locations (4)

Kate.Wilkinson1@health.nsw.gov.au, Sydney, New South Wales, Australia
Westmead Hospital, Sydney, New South Wales, Australia
Sydney Southwest Private Hospital, Sydney, New South Wales, Australia
Cancer Care Wollongong, Sydney, New South Wales, Australia

Collaborators

Fortvita Biologics (USA)Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05290597 on ClinicalTrials.gov

Other trials for Lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Lymphoma →

← Back to all trials